Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	24.79B
Revenue (ttm)	6.02B
Net Income (ttm)	1.23B
Shares Out	1.02B
EPS (ttm)	1.21
PE Ratio	20.15
Forward PE	19.68
Dividend	0.36 (1.49%)
Ex-Dividend Date	May 14, 2025

Volume	11,388,009
Average Volume	6,085,407
Open	24.12
Previous Close	24.13
Day's Range	23.85 - 24.72
52-Week Range	20.36 - 29.30
Beta	-0.30
RSI	40.92
Earnings Date	Apr 18, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in production, marketing, and services related to central nervous system drugs in China. The company offers Duloxetine Hcl, Risperidone, Ziprasidone Hcl, Etomidate Fat Emulsion, Gabapentin, Zaleplon, etc., as well as Iptakalim, an anti-hypertension drug. It also provides penehyquinac acid hydrochloride injection, sufentanil citrate injection, oxeridine fumarate, injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, duloxetine hydrochloride enteric dissolving capsules, olan...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,923
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2024, SHE:002262's revenue was 5.70 billion, an increase of 13.01% compared to the previous year's 5.04 billion. Earnings were 1.14 billion, an increase of 10.28%.